Peripheral neuropeptide y Y1 receptors regulate lipid oxidation and fat accretion

International Journal of Obesity

Volumn 34, Issue 2, 2010, Pages 357-373

  Zhang, L ^a   MacIa, L ^a   Turner, N ^a,b   Enriquez, R F ^a   Riepler, S J ^a   Nguyen, A D ^a   Lin, S ^a   Lee, N J ^a   Shi, Y C ^a   Yulyaningsih, E ^a   Slack, K ^a   Baldock, P A ^b   Herzog, H ^a,b   Sainsbury, A ^a,b  

^a GARVAN INSTITUTE OF MEDICAL RESEARCH   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

Energy balance; Fat accretion; Lipid oxidation; Neuropeptide Y; Y1 receptor

Indexed keywords

3 HYDROXYACYL COENZYME A DEHYDROGENASE; CARNITINE PALMITOYLTRANSFERASE I; FATTY ACID; INSULIN; MEDIUM CHAIN ACYL COENZYME A DEHYDROGENASE; NEUROPEPTIDE Y; NEUROPEPTIDE Y1 RECEPTOR; ACYL COENZYME A DEHYDROGENASE; CARNITINE PALMITOYLTRANSFERASE; NEUROPEPTIDE Y RECEPTOR; NEUROPEPTIDE Y-Y1 RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BODY COMPOSITION; CALORIMETRY; CONTROLLED STUDY; ENERGY EXPENDITURE; ENZYME ACTIVITY; FATTY ACID BLOOD LEVEL; FATTY ACID OXIDATION; FATTY ACID TRANSPORT; FOOD INTAKE; GENE DELETION; INSULIN BLOOD LEVEL; LIPID OXIDATION; LIPID STORAGE; LUNG GAS EXCHANGE; MITOCHONDRIAL RESPIRATION; MOUSE; NONHUMAN; OBESITY; PHYSICAL ACTIVITY; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; REGULATORY MECHANISM; RNA EXTRACTION; SIGNAL TRANSDUCTION; TISSUE HOMOGENATE; WESTERN BLOTTING; ANIMAL; ENERGY METABOLISM; FEMALE; HOMEOSTASIS; MALE; METABOLISM; MITOCHONDRION; MOTOR ACTIVITY; OXIDATION REDUCTION REACTION; PATHOPHYSIOLOGY; PHYSIOLOGY;

3-HYDROXYACYL COA DEHYDROGENASES; ACYL-COA DEHYDROGENASE; ANIMALS; BODY COMPOSITION; CARNITINE O-PALMITOYLTRANSFERASE; ENERGY METABOLISM; FATTY ACIDS; FEMALE; HOMEOSTASIS; MALE; MICE; MITOCHONDRIA; MOTOR ACTIVITY; NEUROPEPTIDE Y; OBESITY; OXIDATION-REDUCTION; RECEPTORS, NEUROPEPTIDE Y;

MUS;

EID: 76749158785     PISSN: 03070565     EISSN: 14765497     Source Type: Journal    
DOI: 10.1038/ijo.2009.232     Document Type: Article

References (91)

1. Raposinho PD, Pierroz DD, Broqua P, White RB, Pedrazzini T, Aubert ML. Chronic administration of neuropeptide Y into the lateral ventricle of C57BL/6J male mice produces an obesity syndrome including hyperphagia, hyperleptinemia, insulin resistance, and hypogonadism. Mol Cell Endocrinol 2001; 185: 195-204.
2. Sainsbury A, Rohner-Jeanrenaud F, Cusin I, Zakrzewska KE, Halban PA, Gaillard RC et al. Chronic central neuropeptide Y infusion in normal rats: status of the hypothalamo-pituitary-adrenal axis, and vagal mediation of hyperinsulinaemia. Diabetologia 1997; 40: 1269-1277.
3. Lin EJ, Sainsbury A, Lee NJ, Boey D, Couzens M, Enriquez R et al. Combined deletion of Y1, Y2 and Y4 receptors prevents hypothalamic NPY overexpression-induced hyperinsulinemia despite persistence of hyperphagia and obesity. Endocrinology 2006; 147: 5094-5101.
4. Kotz CM, Briggs JE, Grace MK, Levine AS, Billington CJ. Divergence of the feeding and thermogenic pathways influenced by NPY in the hypothalamic PVN of the rat. Am J Physiol 1998; 275: R471-R477.
5. Hwa JJ, Witten MB, Williams P, Ghibaudi L, Gao J, Salisbury BG et al. Activation of the NPY Y5 receptor regulates both feeding and energy expenditure. Am J Physiol 1999; 277: R1428-R1434.
6. Stanley BG, Kyrkouli SE, Lampert S, Leibowitz SF. Neuropeptide Y chronically injected into the hypothalamus: a powerful neuro-chemical inducer of hyperphagia and obesity. Peptides 1986; 7: 1189-1192.
7. Billington CJ, Briggs JE, Grace M, Levine AS. Effects of intracer-ebroventricular injection of neuropeptide Y on energy metabolism. Am J Physiol 1991; 260: R321-R327.
8. Billington CJ, Briggs JE, Harker S, Grace M, Levine AS. Neuro-peptide Y in hypothalamic paraventricular nucleus: a center coordinating energy metabolism. Am J Physiol 1994; 266: R1765-R1770.
9. Szreder Z, Hori T, Kaizuka Y. Thermoregulatory effect of intracerebral injections of neuropeptide Y in rats at different environmental temperatures. Gen Pharmacol 1994; 25: 85-91.
10. Currie PJ, Coscina DV. Dissociated feeding and hypothermic effects of neuropeptide Y in the paraventricular and perifornical hypothalamus. Peptides 1995; 16: 599-604.
11. Zarjevski N, Cusin I, Vettor R, Rohner-Jeanrenaud F, Jeanrenaud B. Intracerebroventricular administration of neuropeptide Y to normal rats has divergent effects on glucose utilization by adipose tissue and skeletal muscle. Diabetes 1994; 43: 764-769.
12. Zarjevski N, Cusin I, Vettor R, Rohner-Jeanrenaud F, Jeanrenaud B. Chronic intracerebroventricular neuropeptide-Y administration to normal rats mimics hormonal and metabolic changes of obesity. Endocrinology 1993; 133: 1753-1758.
13. Menendez JA, McGregor IS, Healey PA, Atrens DM, Leibowitz SF. Metabolic effects of neuropeptide Y injections into the paraven-tricular nucleus of the hypothalamus. Brain Res 1990; 516: 8-14.
14. Currie PJ, Coscina DV, Bishop C, Coiro CD, Koob GF, Rivier J et al. Hypothalamic paraventricular nucleus injections of urocortin alter food intake and respiratory quotient. Brain Res 2001; 916: 222-228.
15. Henry M, Ghibaudi L, Gao J, Hwa JJ. Energy metabolic profile of mice after chronic activation of central NPY Y1, Y2, or Y5 receptors. Obes Res 2005; 13: 36-47.
16. Blomqvist AG, Herzog H. Y-receptor subtypesFhow many more? Trends Neurosci 1997; 20: 294-298.
17. Kanatani A, Hata M, Mashiko S, Ishihara A, Okamoto O, Haga Y et al. A typical Y1 receptor regulates feeding behaviors: effects of a potent and selective Y1 antagonist, J-115814. Mol Pharmacol 2001; 59: 501-505.
18. Kanatani A, Kanno T, Ishihara A, Hata M, Sakuraba A, Tanaka T et al. The novel neuropeptide Y Y(1) receptor antagonist J-104870: a potent feeding suppressant with oral bioavailability. Biochem Biophys Res Commun 1999; 266: 88-91.
19. Haynes AC, Arch JR, Wilson S, McClue S, Buckingham RE. Characterisation of the neuropeptide Y receptor that mediates feeding in the rat: a role for the Y5 receptor? Regul Pept 1998; 75-76: 355-361.
20. Antal-Zimanyi I, Bruce MA, Leboulluec KL, Iben LG, Mattson GK, McGovern RT et al. Pharmacological characterization and appetite suppressive properties of BMS-193885, a novel and selective neuropeptide Y(1) receptor antagonist. Eur J Pharmacol 2008; 590: 224-232.
21. Mullins D, Kirby D, Hwa J, Guzzi M, Rivier J, Parker E. Identification of potent and selective neuropeptide Y Y(1) receptor agonists with orexigenic activity in vivo. Mol Pharmacol 2001; 60: 534-540.
22. Sainsbury A, Bergen HT, Boey D, Bamming D, Cooney GJ, Lin S et al. Y2Y4 receptor double knockout protects against obesity due to a high-fat diet or Y1 receptor deficiency in mice. Diabetes 2006; 55: 19-26.
23. Baldock PA, Allison SJ, Lundberg P, Lee NJ, Slack K, Lin EJ et al. Novel role of Y1 receptors in the coordinated regulation of bone and energy homeostasis. J Biol Chem 2007; 282: 19092-19102.
24. Pedrazzini T, Seydoux J, Kunstner P, Aubert JF, Grouzmann E, Beermann F et al. Cardiovascular response, feeding behavior and locomotor activity in mice lacking the NPY Y1 receptor. Nat Med 1998; 4: 722-726.
25. Kushi A, Sasai H, Koizumi H, Takeda N, Yokoyama M, Nakamura M. Obesity and mild hyperinsulinemia found in neuropeptide Y-Y1 receptor-deficient mice. Proc Natl Acad Sci USA 1998; 95: 15659-15664.
26. Leibel RL, Rosenbaum M, Hirsch J. Changes in energy expenditure resulting from altered body weight. N Engl J Med 1995; 332: 621-628.
27. Berglund MM, Hipskind PA, Gehlert DR. Recent developments in our understanding of the physiological role of PP-fold peptide receptor subtypes. Exp Biol Med (Maywood) 2003; 228: 217-244.
28. Goumain M, Voisin T, Lorinet AM, Laburthe M. Identification and distribution of mRNA encoding the Y1, Y2, Y4, and Y5 receptors for peptides of the PP-fold family in the rat intestine and colon. Biochem Biophys Res Commun 1998; 247: 52-56.
29. Yang K, Guan H, Arany E, Hill DJ, Cao X. Neuropeptide Y is produced in visceral adipose tissue and promotes proliferation of adipocyte precursor cells via the Y1 receptor. FASEB J 2008; 7: 7.
30. Serradeil-Le Gal C, Lafontan M, Raufaste D, Marchand J, Pouzet B, Casellas P et al. Characterization of NPY receptors controlling lipolysis and leptin secretion in human adipocytes. FEBS Lett 2000; 475: 150-156.
31. Kuo LE, Kitlinska JB, Tilan JU, Li L, Baker SB, Johnson MD et al. Neuropeptide Y acts directly in the periphery on fat tissue and mediates stress-induced obesity and metabolic syndrome. Nat Med 2007; 13: 803-811.
32. Dark J, Pelz KM. NPY Y1 receptor antagonist prevents NPY-induced torpor-like hypothermia in cold-acclimated Siberian hamsters. Am J Physiol Regul Integr Comp Physiol 2008; 294: R236-R245.
33. Dark J, Pelz KM. ICV NPY Y1 receptor agonist but not Y5 agonist induces torpor-like hypothermia in cold-acclimated Siberian hamsters. Am J Physiol Regul Integr Comp Physiol 2007; 292: R2299-R2311.
34. Trivedi PG, Yu H, Trumbauer M, Chen H, Van der Ploeg LH, Guan X. Differential regulation of neuropeptide Y receptors in the brains of NPY knock-out mice. Peptides 2001; 22: 395-403.
35. Wittmann W, Loacker S, Kapeller I, Herzog H, Schwarzer C. Y1-receptors regulate the expression of Y2-receptors in distinct mouse forebrain areas. Neuroscience 2005; 136: 241-250.
36. Lin S, Boey D, Couzens M, Lee N, Sainsbury A, Herzog H. Compensatory changes in [125I]-PYY binding in Y receptor knockout mice suggest the potential existence of further Y receptor(s). Neuropeptides 2005; 39: 21-28.
37. Marsh DJ, Hollopeter G, Kafer KE, Palmiter RD. Role of the Y5 neuropeptide Y receptor in feeding and obesity. Nat Med 1998; 4: 718-721.
38. Howell OW, Scharfman HE, Herzog H, Sundstrom LE, Beck-Sickinger A, Gray WP. Neuropeptide Y is neuroproliferative for post-natal hippocampal precursor cells. J Neurochem 2003; 86: 646-659.
39. Kuhn R, Schwenk F, Aguet M, Rajewsky K. Inducible gene targeting in mice. Science 1995; 269: 1427-1429.
40. Ferrannini E. The theoretical bases of indirect calorimetry: a review. Metabolism 1988; 37: 287-301.
41. Frayn KN. Calculation of substrate oxidation rates in vivo from gaseous exchange. J Appl Physiol 1983; 55: 628-634.
42. McLean JA, Tobin G. Animal and Human Calorimetry. Cambridge University Press: New York, 1987. pp 352.
43. Turner N, Bruce CR, Beale SM, Hoehn KL, So T, Rolph MS et al. Excess lipid availability increases mitochondrial fatty acid oxidative capacity in muscle: evidence against a role for reduced fatty acid oxidation in lipid-induced insulin resistance in rodents. Diabetes 2007; 56: 2085-2092.
44. Molero JC, Waring SG, Cooper A, Turner N, Laybutt R, Cooney GJ et al. Casitas b-lineage lymphoma-deficient mice are protected against high-fat diet-induced obesity and insulin resistance. Diabetes 2006; 55: 708-715.
45. Djouadi F, Riveau B, Merlet-Benichou C, Bastin J. Tissue-specific regulation of medium-chain acyl-CoA dehydrogenase gene by thyroid hormones in the developing rat. Biochem J 1997; 324 (Pt 1): 289-294.
46. Franklin KBJ, Paxinos G. The mouse brain in stereotaxic coordinates. Academic Press: California 1997, pp 47-48.
47. Saggerson ED, Carpenter CA. Carnitine palmitoyltransferase and carnitine octanoyltransferase activities in liver, kidney cortex, adipocyte, lactating mammary gland, skeletal muscle and heart. FEBS Lett 1981; 129: 229-232.
48. McGarry JD, Mills SE, Long CS, Foster DW. Observations on the affinity for carnitine, and malonyl-CoA sensitivity, of carnitine palmitoyltransferase I in animal and human tissues. Demonstration of the presence of malonyl-CoA in non-hepatic tissues of the rat. Biochem J 1983; 214: 21-28.
49. Lin J, Handschin C, Spiegelman BM. Metabolic control through the PGC-1 family of transcription coactivators. Cell Metab 2005; 1: 361-370.
50. Daniels AJ, Matthews JE, Slepetis RJ, Jansen M, Viveros OH, Tadepalli A et al. High-affinity neuropeptide Y receptor antagonists. Proc Natl Acad Sci USA 1995; 92: 9067-9071.
51. Fam BC, Morris MJ, Hansen MJ, Andrikopoulos S, Proietto J, Thorburn AW. Modulation of central leptin sensitivity and energy balance in a rat model of diet-induced obesity. Diabetes Obes Metab 2007; 9: 840-852.
52. Iossa S, Mollica MP, Lionetti L, Crescenzo R, Botta M, Liverini G. Skeletal muscle oxidative capacity in rats fed high-fat diet. Int J Obes Relat Metab Disord 2002; 26: 65-72.
53. Levine JA, Eberhardt NL, Jensen MD. Role of nonexercise activity thermogenesis in resistance to fat gain in humans. Science 1999; 283: 212-214.
54. Tran TT, Yamamoto Y, Gesta S, Kahn CR. Beneficial effects of subcutaneous fat transplantation on metabolism. Cell Metab 2008; 7: 410-420.
55. Hocking SL, Chisholm DJ, James DE. Studies of regional adipose transplantation reveal a unique and beneficial interaction between subcutaneous adipose tissue and the intra-abdominal compartment. Diabetologia 2008; 51: 900-902.
56. Ravussin E, Lillioja S, Anderson TE, Christin L, Bogardus C. Determinants of 24-hour energy expenditure in man. Methods and results using a respiratory chamber. J Clin Invest 1986; 78: 1568-1578.
57. Vogels N, Westerterp-Plantenga MS. Successful long-term weight maintenance: a 2-year follow-up. Obesity (Silver Spring) 2007; 15: 1258-1266.
58. Vogels N, Diepvens K, Westerterp-Plantenga MS. Predictors of long-term weight maintenance. Obes Res 2005; 13: 2162-2168.
59. Illner K, Brinkmann G, Heller M, Bosy-Westphal A, Muller MJ. Metabolically active components of fat free mass and resting energy expenditure in nonobese adults. Am J Physiol Endocrinol Metab 2000; 278: E308-E315.
60. Muller MJ. Hepatic energy and substrate metabolism: a possible metabolic basis for early nutritional support in cirrhotic patients. Nutrition 1998; 14: 30-38.
61. Kelley DE, Reilly JP, Veneman T, Mandarino LJ. Effects of insulin on skeletal muscle glucose storage, oxidation, and glycolysis in humans. Am J Physiol 1990; 258: E923-E929.
62. Rasmussen BB, Wolfe RR. Regulation of fatty acid oxidation in skeletal muscle. Annu Rev Nutr 1999; 19: 463-484.
63. Bruce CR, Brolin C, Turner N, Cleasby ME, Van der Leij FR, Cooney GJ et al. Overexpression of carnitine palmitoyltransferase I in skeletal muscle in vivo increases fatty acid oxidation and reduces triacylglycerol esterification. Am J Physiol Endocrinol Metab 2007; 292: E1231-E1237.
64. Tanaka K, Yokota I, Coates PM, Strauss AW, Kelly DP, Zhang Z et al. Mutations in the medium chain acyl-CoA dehydrogenase (MCAD) gene. Hum Mutat 1992; 1: 271-279.
65. Jequier E. Leptin signaling, adiposity, and energy balance. Ann N Y Acad Sci 2002; 967: 379-388.
66. Pedrazzini T. Importance of NPY Y1 receptor-mediated pathways: assessment using NPY Y1 receptor knockouts. Neuropeptides 2004; 38: 267-275.
67. Chelikani PK, Haver AC, Reeve Jr JR, Keire DA, Reidelberger RD. Daily, intermittent intravenous infusion of peptide YY(3-36) reduces daily food intake and adiposity in rats. Am J Physiol Regul Integr Comp Physiol 2006; 290: R298-R305.
68. Pralong FP, Gonzales C, Voirol MJ, Palmiter RD, Brunner HR, Gaillard RC et al. The neuropeptide Y Y1 receptor regulates leptin-mediated control of energy homeostasis and reproductive functions. FASEB J 2002; 16: 712-714.
69. Gonzales C, Voirol MJ, Giacomini M, Gaillard RC, Pedrazzini T, Pralong FP. The neuropeptide Y Y1 receptor mediates NPY-induced inhibition of the gonadotrope axis under poor metabolic conditions. FASEB J 2004; 18: 137-139.
70. DEon TM, Souza SC, Aronovitz M, Obin MS, Fried SK, Greenberg AS. Estrogen regulation of adiposity and fuel partitioning.Evidence of genomic and non-genomic regulation of lipogenic and oxidative pathways. J Biol Chem 2005; 280: 35983-35991.
71. Ogawa S, Chan J, Gustafsson JA, Korach KS, Pfaff DW. Estrogen increases locomotor activity in mice through estrogen receptor alpha: specificity for the type of activity. Endocrinology 2003; 144: 230-239.
72. Mattiasson I, Rendell M, Tornquist C, Jeppsson S, Hulthen UL. Effects of estrogen replacement therapy on abdominal fat compartments as related to glucose and lipid metabolism in early postmenopausal women. Horm Metab Res 2002; 34: 583-588.
73. Mudali S, Dobs AS. Effects of testosterone on body composition of the aging male. Mech Ageing Dev 2004; 125: 297-304.
74. Poehlman ET. Menopause, energy expenditure, and body composition. Acta Obstet Gynecol Scand 2002; 81: 603-611.
75. Blouin K, Despres JP, Couillard C, Tremblay A, Prud'homme D, Bouchard C et al. Contribution of age and declining androgen levels to features of the metabolic syndrome in men. Metabolism 2005; 54: 1034-1040.
76. Karl T, Burne TH, Herzog H. Effect of Y1 receptor deficiency on motor activity, exploration, and anxiety. Behav Brain Res 2006; 167: 87-93.
77. Bartness TJ, Song CK. Thematic review series: adipocyte biology. Sympathetic and sensory innervation of white adipose tissue. J Lipid Res 2007; 48: 1655-1672.
78. Carey GB. Mechanisms regulating adipocyte lipolysis. Adv Exp Med Biol 1998; 441: 157-170.
79. Egawa M, Yoshimatsu H, Bray GA. Neuropeptide Y suppresses sympathetic activity to interscapular brown adipose tissue in rats. Am J Physiol 1991; 260: R328-R334.
80. Michalkiewicz M, Knestaut KM, Bytchkova EY, Michalkiewicz T. Hypotension and reduced catecholamines in neuropeptide Y transgenic rats. Hypertension 2003; 41: 1056-1062.
81. Yang SN, Finnman UB, Fuxe K. The non-peptide neuropeptide Y Y1 receptor antagonist BIBP3226 blocks the [Leu31,Pro34]neuro-peptide Y-induced modulation of alpha 2-adrenoceptors in the nucleus tractus solitarii of the rat. Neuroreport 1996; 7: 2701-2705.
82. Glass MJ, Chan J, Pickel VM. Ultrastructural localization of neuropeptide Y Y1 receptors in the rat medial nucleus tractus solitarius: relationships with neuropeptide Y or catecholamine neurons. J Neurosci Res 2002; 67: 753-765.
83. Bowers RR, Festuccia WT, Song CK, Shi H, Migliorini RH, Bartness TJ. Sympathetic innervation of white adipose tissue and its regulation of fat cell number. Am J Physiol Regul Integr Comp Physiol 2004; 286: R1167-R1175.
84. Labelle M, Boulanger Y, Fournier A, St Pierre S, Savard R. Tissue-specific regulation of fat cell lipolysis by NPY in 6-OHDA-treated rats. Peptides 1997; 18: 801-808.
85. Bradley RL, Mansfield JP, Maratos-Flier E. Neuropeptides, including neuropeptide Y and melanocortins, mediate lipolysis in murine adipocytes. Obes Res 2005; 13: 653-661.
86. Valet P, Berlan M, Beauville M, Crampes F, Montastruc JL, Lafontan M. Neuropeptide Y and peptide YY inhibit lipolysis in human and dog fat cells through a pertussis toxin-sensitive G protein. J Clin Invest 1990; 85: 291-295.
87. Castan I, Valet P, Quideau N, Voisin T, Ambid L, Laburthe M et al. Antilipolytic effects of alpha 2-adrenergic agonists, neuropeptide Y, adenosine, and PGE1 in mammal adipocytes. Am J Physiol 1994; 266: R1141-R1147.
88. Phillips JK, McLean AJ, Hill CE. Receptors involved in nerve-mediated vasoconstriction in small arteries of the rat hepatic mesentery. Br J Pharmacol 1998; 124: 1403-1412.
89. Goehler LE, Sternini C. Neuropeptide Y immunoreactivity in the mammalian liver: pattern of innervation and coexistence with tyrosine hydroxylase immunoreactivity. Cell Tissue Res 1991; 265: 287-295.
90. Taborsky Jr GJ, Beltramini LM, Brown M, Veith RC, Kowalyk S. Canine liver releases neuropeptide Y during sympathetic nerve stimulation. Am J Physiol 1994; 266: E804-E812.
91. Padwal RS, Majumdar SR. Drug treatments for obesity: orlistat, sibutramine, and rimonabant. Lancet 2007; 369: 71-77.